T he management of incidental unruptured intracranial aneurysms (UIAs) remains undefined. After the International Study of Unruptured Intracranial Aneurysms (ISUIAs) 1, 2 prospectively showed very low rupture rates of small aneurysms of the anterior circulation, others described the natural course of UIAs. [3] [4] [5] [6] Although the reported rupture rate of small UIAs is low, when they do rupture, they lead to life-threatening subarachnoid hemorrhage (SAH).
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October 2013 in the JR-NET study were registered from 122 Japanese neurointerventional centers with 200 EVT specialists. Clinical and procedural data were entered through a Web site constructed by the Translation Research Informatics Center (Kobe, Japan) and anonymously reviewed by the principal investigators. Each JR-NET and JR-NET2 data set of cerebral aneurysms included the following parameters: demographics (sex, age, date of treatment), clinical data (mRS before and 30 days after EVT), complication data (procedure-related complications, adverse events), treatment parameters (aneurysmal location, size, shape, associated or not with SAH, symptomatic or asymptomatic), and procedural data (number of cerebral aneurysms treated in a single procedure, endovascular techniques, immediate radiographic outcomes, antithrombotic regimen). Table 1 shows the 16 locations of cerebral aneurysms listed in the registration studies. The aneurysms were classified according to maximal diameters of 3, 5, 10 , and 20 mm. Aneurysms <10 mm were also classified as having favorable (neck, ≤4 mm; dome-to-neck ratio, ≥1.5) or wide (neck, >4 mm or dome-to-neck ratio, <1.5) necks. The degree of aneurysm occlusion was defined on the basis of 3-point Raymond classification scale. 12 That is, CO (class I) for complete occlusion, RN (class II) for residual neck, and RA (class III) for residual aneurysm. We also defined incident obstructive aneurysms causing parent artery occlusion as unpredicted parent artery occlusion that differed from parent artery aneurysms that were scheduled for treatment.
Clinical status was defined using the mRS. Morbidity and mortality were defined as deterioration of >0 on the mRS and death related to treatment at 30 days thereafter. Any such changes within 30 days of EVT were considered treatment related.
Data Extraction
All data sets registered as aneurysmal treatment and initially extracted from the JR-NET and JR-NET2 databases were screened in a single session to collect only information about treatment of asymptomatic UIAs. In other words, ruptured aneurysms, dissecting aneurysms, symptomatic UIAs, extracranial aneurysms, aneurysms associated with ruptured or symptomatic aneurysms, and treated UIAs concomitant with other diseases were excluded. We also screened procedures for eligibility criteria comprising pre-(sex, age, date of treatment, preprocedural mRS, aneurysm characteristics), intra-(techniques), and postprocedural status (radiographic outcomes, procedure-related adverse events, and mRS at 30 days). Treatment for intentional parent artery occlusion and nonsaccular aneurysms was also excluded. We thus isolated 1506 (1571 UIAs) and 3067 (3, 196 UIAs) procedures from JR-NET and JR-NET2, respectively, with complete data for almost all variables on which this analysis was based (Figure) . Combining these data from 4573 (4767 UIAs) procedures, 1262 (27.6%) and 3311 (72.4%) men and women, respectively, ranging in age from 6 to 93 (mean, 60.6±11.1) years underwent procedures. The numbers of treated UIAs were 1 (96.1%) of 4395, 2 of 164, 3 of 12, and 4 of 2 procedures (Table 2) .
Statistical Analysis
Mean and frequency data were compared using Student t test and the χ 2 test or Fisher exact test, respectively. Trends were analyzed using the Cochran-Armitage test. All data were statistically analyzed using JMP version 10.0 software (SAS Institute, Cary, NC). The significance threshold was established at P<0.05.
Results

Aneurysm Characteristics
We analyzed periprocedural data from 4767 asymptomatic UIAs. Table 1 shows the features of the aneurysms, 3814 (80.0%) and 953 (20.0%) of which were located in the anterior and posterior circulation, respectively. One third was located in the internal carotid artery-paraclinoid, followed by the internal carotid artery-posterior communicating artery (14.3%), anterior communicating artery (12.3%), bifurcation of basilar artery (10.9%), and middle cerebral artery (6.3%). The maximal diameters of 2476 (51.9%) and 1569 (32.9%) aneurysms were 5 to 9 and 3 to 4 mm, 
Modalities of EVT for UIAs
Of 2155 (45.2%) aneurysms that were scheduled for intraaneurysmal embolization, all were treated by intrasaccular coil embolization using a single microcatheter and coils, and the remaining 2612 (54.8%) underwent adjunctive therapies, including balloon remodeling, 13 
EVT Feasibility and Immediate Radiographic Outcomes
EVT for 102 (2.1%) aneurysms failed ( 
Adverse Events Related to EVT
Procedure-related adverse events occurred in 417 (9.1%) patients and 23.0% of those (n=96; 2.1% of total) had a reduced 30-day mRS (Table 3) . Intracranial hemorrhagic and ischemic complications developed after 90 (2.0%) and 210 (4.6%) procedures, respectively, and 65 aneurysms ruptured intraprocedurally (1.4% per each aneurysm and procedure). We also found 5 aneurysms that had ruptured during the post-treatment period. Ischemic complications significantly decreased annually (P=0.01), but the total complication rates had no significant trend (Table 4) . Analysis according to aneurysm size revealed that total complication rates were higher in aneurysms with very small (<3 mm) and large (≥10 mm) diameters than in those with diameters between 3 and 9 mm ( 
Clinical Outcomes at 30 Days
The 30-day morbidity and mortality rates were 97 (2.12%) and 14 (0.31%) of 4573 procedures, respectively (Table 3 ). All deaths were accompanied by hemorrhagic complications (aneurysmal ruptures, n=10; arterial dissections, n=2; arterial perforation, n=1) except one with ischemic complications caused by branch occlusion. No death was associated with other systemic conditions, such as coronary disease, pneumonia, or cancer.
Discussion
The incidence of detecting incidental asymptomatic UIAs has recently increased together with increasing opportunities for radiological assessments and developments in neuroimaging devices. However, consensus has not been reached on UIA management, which requires understanding of the natural history balanced against risks of treatment and long-term protection.
The largest study of the natural course of UIAs was compiled in 1998 by ISUIA investigators who first reported 0.5% annual rates of SAH for aneurysms <10 mm and 0.05% annual rates in patients with and without a history of SAH. On the basis of reports thereafter about the natural history, especially of small UIAs, risk factors for aneurysmal rupture and SAH resulting from small aneurysms, the Japan Stroke Society released statements for the management of UIAs within guidelines for the management of stroke, 15 and relatively clear recommendations for UIA management have also been reported. 16 Morita et al 6 (Unruptured Cerebral Aneurysm Study [UCAS] Japan Investigators) documented 111 patients with a 0.95% annual rate of rupture during a follow-up comprising 11 660 aneurysm-years. However, the results of clipping UIAs and coiling are difficult to compare. Although some prospective randomized studies, such as the ISAT 17 or Barrow Trial, 18 have compared coiled with clipped ruptured aneurysms, the results for UIAs were determined from aggregate analyses 19 or analyses of recent databases 20, 21 because designing randomized controlled trials is difficult.
We aimed to clarify the current risks and short-term outcomes of EVT for UIAs in Japan, considering individual UIA management. We analyzed the outcomes of EVT for asymptomatic UIAs between 2005 and 2009 on the basis of information accumulated from the JR-NET and JR-NET2 databases created from information provided by >100 institutions throughout Japan. Most EVT for asymptomatic UIAs was performed by Japanese Society for Neuroendovascular Therapy-certified EVT specialists. Thus, this study is the first large cohort investigation of the nationwide results of EVT for asymptomatic UIAs.
In the present study, most of the patients were women and anterior circulation aneurysms were the most prevalent, which reflected the findings of the ISUIA 1 and Analysis of Treatment by Endovascular approach of Non ruptured Aneurysms (ATENA) 11 studies. However, the patients were a mean of 10 years, and most aneurysms (87.3%) were <10 mm. Although the Japanese guidelines recommend treating UIAs ≥5 mm in maximal diameter, 15 UIAs <5 mm account for 35.4% of the total; Oishi et al 10 reported that 223 (44.6%) of 500 small (<10 mm in diameter) treated UIAs were <5 mm. As part of the annual health checks characteristic of the unique Japanese healthcare system, complete physical examinations and whole brain screenings are widespread, and more small UIAs have been discovered through these routine procedures than elsewhere. Moreover, the Japanese insurance system covers treatment for such UIAs if the patient elects to proceed. Thus, small UIAs have abundant opportunities for treatment in Japan.
Some retrospective single-center results of EVT for UIAs have been reported. Although Im et al 9 and Oishi et al 10 have recently reported comparatively large-volume series, most 
Feasibility and Clinical Outcomes of EVT
The 2.1% failure rate in the present study was lower than those in the ATENA (4.3%) and other (3.8% to 10%) studies. The failure rates were significantly higher and lower for small aneurysms with wide and narrow necks, respectively, and tended to increase as aneurysms decreased. Failure rates did not significantly differ between aneurysms of the anterior and aneurysms of the posterior circulation.
The ATENA study that defined morbidity at 1 month after treatment as mRS 2 to 5 and a preoperative mRS>1 as any increase in the mRS, reported morbidity and mortality rates of 2.6% and 1.1%, respectively. These rates in retrospective case series range from 0% to 7.7% and from 0% to 1.7%, respectively. One systematic review found that at 1 month, 1.8% of patients had died in addition to 4.7% with unfavorable outcome rates, including death. 22 In addition, Brinjikji et al 21 found from the 2001 to 2008 Nationwide Inpatient Sample hospital discharge database that 4.9% patients were discharged to long-term facilities and 0.6% died after undergoing EVT for UIAs. Recent randomized controlled trials of bioactive coils have also shown risks of EVTs. The HydroCoil Endovascular Aneurysm Occlusion and Packing Study (HELPS) 23 found mRS 3 to 6 at 18 months in 10.3% of patients with target aneurysms that had not ruptured recently. Besides, 2.3% of the patients treated for a UIA in the Cerecyte trial 24 had mRS 2 to 5 at discharge, and no deaths were determined. We defined morbidity and mortality as any deterioration >0 on the mRS and any death related to treatment, respectively, which were similar to Oishi's definitions. 10 We determined 2.1% and 0.3% morbidity and mortality rates from JR-NET and JR-NET2 data, respectively, which we think are justified. We could not evaluate cognitive status as in the ISUIA study, and because neurologists did not always perform independent neurological examinations, we might have underestimated morbidity.
Radiographic Outcomes
The other case series used various classifications. To compare rates of insufficient radiographic outcomes of coil embolization among studies, we determined how many were defined as incomplete occlusion (<90%) or residual aneurysm. The radiographic outcomes of coil embolization were insufficient in 19.3% of aneurysms in the ATENA study, 1.2% to 20.8% in other studies, and 10.0% in the present study. We also determined the initial radiographic outcomes of the HELPS 23 and the Cerecyte trial 24 ; 14.5% were insufficient in the former and 11.7% were insufficient in the latter, 24 which used bare platinum coils. The radiographic outcomes herein usually depended on the judgment of the treating physicians, and thus poor outcomes might have been underestimated, which the second report of the ATENA study also considers.
25
Adverse Events
The rate of procedure-related complications is 15.4% in the ATENA study (including 2.6% and 7.1% hemorrhagic and ischemic complications, respectively) and 2.5% to 28% in 
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other studies. This variation might be associated with studies defining complications differently. We found that intra-or postprocedural complications were associated with 417 (9.1%) of 4573 procedures within 30 days and comprised intracranial hemorrhagic and ischemic complications in 2.0% and 4.6% of those, respectively. About 75% of these were asymptomatic or transiently symptomatic and did not result in mRS deterioration. Systemic heparinization is recommended before placing guiding catheters to maintain activated coagulation times within 250 to 300 seconds and to avoid thromboembolic or ischemic complications of UIAs. 26 Antiplatelet therapy has also been recommended to prevent thromboembolic complications. 27, 28 Here, intraprocedural systemic heparinization was applied in 98.1% of procedures, and pre-and postprocedural oral antiplatelet agents were applied significantly more often every year. Continuous intravenous anticoagulation therapy with not only heparin but also antithrombin agents (Argatroban) 29 has also been added. Ischemic complications decreased annually, and the frequency of thrombogenic adjunctive techniques has increased. We could not identify the efficacy of antiplatelet medication against ischemic complications, and thus prospective studies are required. We found significantly higher complication rates, especially ischemic, for aneurysms of the posterior as compared with the anterior circulation, which contradicted the findings of a recent systematic review. 22 Recently, UCAS Japan found similar rupture rates of aneurysms in the posterior and anterior circulation, but those of aneurysms in the internal carotid arteryposterior communicating artery and anterior communicating artery were higher. 6 The lower complication rate associated with aneurysms of the posterior circulation should be further investigated. Notably, larger and smaller aneurysms were associated with higher ischemic and hemorrhagic complication rates, respectively, and the risks of hemorrhagic complications and insufficient radiographic results were significantly higher in tiny aneurysms <3 mm than in those of UIAs 5 to 9 mm (odds ratios, 2.8 [P=0.04] and 2.1 [P=0.09], respectively). In contrast, risks of failure or total complications were not significantly increased in tiny aneurysms <3 mm. These findings should be considered in the management of small UIAs. Intraprocedural aneurysmal rupture occurred at a rate of 2.6% per procedure in the ATENA study, 11 1.4% per aneurysm in the series of Oishi et al, 10 and 1.9% per patient treated for a UIA in the Cerecyte trial. 24 We found similar rates of 1.4%. Because 10 of 65 aneurysmal ruptures led to mortality, intraprocedural aneurysmal rupture must be scrupulously avoided. We found 5 (0.1%) post-treatment aneurysmal ruptures, although such events in the HELPS or the Cerecyte trial were not reported. Of these 5 ruptures, only 1 was associated with intraprocedural rupture. All of them led to poor clinical outcomes (mRS, (4) (5) (6) . On the basis of our findings of complication rates, physicians should reconsider treatment indications for smaller aneurysms, such as those that were treated in the Japanese system and which we determined before comparing the risk of complications with the low risk of rupture (ISUIA2 or UCAS Japan).
Limitations
We extracted information about the outcomes of EVT for asymptomatic UIAs from those of all EVTs that were retrospectively registered by physicians at several neurointerventional centers but they do not represent the nationwide total. The Japan Neurosurgical Society found that 3053 EVTs were performed to treat unruptured cerebral aneurysms during 2006. Our database included 1103 unruptured cerebral aneurysms for the same period, which was 36.1% of the total. Furthermore, aneurysms that were treated more than once could not be excluded from the present study. Our results could be inherently biased because the treating physicians assessed radiographic and clinical outcomes and procedurerelated complications. Decisions on treatment indications might have also introduced inclusion bias. To understand the full outcomes of EVTs for UIAs in Japan, Japanese Society for Neuroendovascular Therapy will continue to collect data from all certified neurointerventionists throughout Japan. In addition, a prospective study, especially of EVT for unruptured aneurysms, might be warranted. Intracranial stentassisted techniques and bioactive coil usage were not assessed because these devices were not fully approved in Japan during the study period. This report simply describes the outcomes of EVT for asymptomatic UIAs, which did not include surgically treated or untreated UIAs, and the population of patients with asymptomatic UIAs was not representative of the total.
Conclusions
This is the largest nationwide study of the outcomes of EVT for UIAs in Japan in which the immediate radiographic Murayama et al., 1999 Murayama et al., -1991 Murayama et al., .8-1998 
